<DOC>
	<DOCNO>NCT00986440</DOCNO>
	<brief_summary>Monotherapy treatment CS-7017 ass progression-free-survival ( PFS ) subject achieve objective response Disease Control first line therapy Folinic acid ( leucovorin ) , Fluorouracil ( 5-FU ) , Oxaliplatin ( Eloxatin ) know FOLFOX ; Folinic acid ( leucovorin ) , Fluorouracil ( 5-FU ) , irinotecan ( Camptosar ) know FOLFIRI .</brief_summary>
	<brief_title>Study CS-7017 Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Efatutazone</mesh_term>
	<criteria>Patients histologically confirm , metastatic CRC achieve confirm maximal benefit DC follow treatment standard first line chemotherapy 5fluoropyrimidine plus either oxaliplatin irinotecan . Patients enter onto trial within 8 week complete first line therapy ; If CR achieve : measurable disease , i.e . minimum one unidimensionallymeasurable target lesion accord RECIST ( Response Evaluation Criteria Solid Tumors ) ; Age &gt; = 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) = &lt; 2 study entry ; Resolution toxic effect prior therapy ( except alopecia ) NCI CTCAE , Version 3.0 , grade = &lt; 1 ; Adequate organ bone marrow function evidence : Haemoglobin &gt; = 10 g/dL ( transfusion and/or growth factor support allow ) ; Absolute neutrophil count ( ANC ) &gt; = 1.5 x 109/L ; Platelet count &gt; = 100 x 109/L ; Serum creatinine = &lt; 1.5 x ULN creatinine clearance &gt; 60 mL/min ; AST alkaline phosphatase &lt; 2.5 x ULN without liver metastasis = &lt; 5.0 x ULN liver metastasis ; Total bilirubin = &lt; 2.0 x ULN ; Prothrombin time ( PT ) /International Normalised Ratio ( INR ) within normal limit ( WNL ) unless therapeutically anticoagulated ; Women childbearing potential men must willing consent use highly effective method contraception ( eg , hormonal contraceptive , bilateral tubal ligation , barrier spermicide , intrauterine device ) treatment least 3 month thereafter ; Males potential father child must use two follow method contraception acceptable study ( e.g . hormonal contraceptive , bilateral tubal ligation , barrier spermicide , intrauterine device ) trial treatment least 3 month thereafter . All female subject childbearing potential must negative pregnancy test ( plasma urine ) result within 7 day initiate study treatment ; Baseline laboratory test tumor assessment must perform within 2 week initiate study treatment ; Subjects must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) must sign date IECapproved ICF performance study specific procedure test . Anticipation need major surgical procedure RT study ; Treatment chemotherapy , hormonal therapy , minor surgery , investigational agent within 4 week study enrolment . Treatment immunotherapy , biological therapy , major surgery within 6 week study enrolment . Treatment RT within 1 week study enrolment . History follow condition : diabetes mellitus require treatment insulin oral agent ; Concomitant use TZDs ; Myocardial infarction significant impairment cardiac function ( e.g. , ejection fraction = &lt; 50 % ) ; severe/unstable angina pectoris ; coronary/peripheral artery bypass graft ; congestive heart failure ; cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) , pulmonary embolism , clinically significant thromboembolic event ; clinically significant pulmonary disease ( e.g. , severe chronic obstructive pulmonary disease [ COPD ] asthma ) ; Brain metastasis ; uncontrolled seizure disorder ; spinal cord compression ; carcinomatous meningitis ; Pleural pericardial effusion . Subjects minimal pleural effusion may eligible upon request Investigator approval Sponsor ; Clinically significant active infection require antibiotic therapy Human Immunodeficiency Virus ( HIV ) positive subject receive antiretroviral therapy ; Pregnant breast feeding ; Known history severe hypersensitivity reaction component CS 7017 formulation ; Serious intercurrent medical psychiatric illness condition opinion Investigator would impair ability give inform consent unacceptably reduce protocol compliance safety study treatment ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>